C&R Research Inc is a Korea-based company is mainly engaged in the clinical trial agency and drug development business. The Company is mainly engaged in the provision of comprehensive early-stage clinical services in the areas of medical writing, regulatory matters, data management, biostatistics and others. The Company is mainly engaged in the provision of consulting services including initial clinical development, clinical trial development, global clinical trial development and others. In addition, the Company is also engaged in the operation of clinical trial training center.

Employees

510

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 04/06/2026			5-day change	1st Jan Change
550.00 ^KRW	+7.63%		0.00%	-38.89%

03-30	C&R Research Inc wins 11.5 billion won order	RE
11-06	C&R Research Inc. announces Annual dividend, payable on April 13, 2026	CI

Market Cap	31.61B 20.62M 18.11M 16.69M 15.62M 29.27M 1.95B 29.77M 200M 77.57M 958M 77.4M 75.73M 3.33B	P/E 2024	17.1x	P/E 2025	19.9x
Enterprise Value	28.93B 18.87M 16.58M 15.28M 14.3M 26.8M 1.79B 27.25M 183M 71.01M 877M 70.85M 69.32M 3.05B	EV / Sales 2024	0.98x	EV / Sales 2025	0.75x
Free-Float	36.73%	Yield 2024	0.86%	Yield 2025	-

03-30	C&R Research Inc wins 11.5 billion won order	RE
11-06	C&R Research Inc. announces Annual dividend, payable on April 13, 2026	CI
22/03/23	C&R Research Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
08/12/21	C&R Research Co., Ltd. completed the acquisition of NH Special Purpose Acquisition 17 Company in a reverse merger transaction.	CI
23/06/21	C&R Research Co., Ltd. signed an agreement to acquire NH Special Purpose Acquisition 17 Company in a reverse merger transaction.	CI
17/09/20	Nh Special Purpose Acquisition 17 Company has completed an IPO in the amount of KRW 12 billion.	CI
01/07/20	Nh Special Purpose Acquisition 17 Company has filed an IPO.	CI

1 day	+7.63%
Current month	-3.34%
1 month	-13.66%
3 months	-32.10%
6 months	-42.53%
Current year	-38.89%

C&R Research Inc. Stock

Stocks

A359090

KR7359090008

Biotechnology & Medical Research

Valuation: C&R Research Inc.

Chart: C&R Research Inc.

Latest news : C&R Research Inc.

Quotes and Performance

Course Extremes

Managers and Directors: C&R Research Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

1 month	494	647
Current year	494	974
1 year	494	1,178
3 years	494	2,395
5 years	494	2,680
10 years	494	2,680

Manager	Title	Age	Since
Moon-Tae Yoon CEO	Chief Executive Officer	74	08/12/2021
Kyu-Sun Moon DFI	Director of Finance/CFO	49	-
Byeong-in Ahn PSD	President	56	-

Director	Title	Age	Since
Moon-Tae Yoon BRD	Director/Board Member	74	08/12/2021
Jung-Hee Park BRD	Director/Board Member	62	28/10/2021
Byung-In Yoon BRD	Director/Board Member	46	-

Date	Insider	Type	Quantity	% Market Cap.
22/12/24	Yun-ho Kim	Sell	73,163	0.1290%
23/09/24	Jin-hak Kim	Buy	6,675	0.0118%
23/09/24	Jin-hak Kim	Buy	13,325	0.0236%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
C&R RESEARCH INC.	+7.63%	0.00%	-47.47%	-55.65%	20.55M
LONZA GROUP AG	+2.96%	+4.21%	-8.16%	-2.76%	43.24B
REVOLUTION MEDICINES, INC.	+1.74%	+7.94%	+322.13%	+562.30%	35.25B
BEONE MEDICINES AG	+1.35%	+4.27%	+6.86%	+53.49%	30.22B
IQVIA HOLDINGS INC.	+2.32%	-3.87%	+11.00%	-19.54%	28.01B
CELLTRION, INC.	-4.75%	-8.29%	+3.90%	+13.88%	24.08B
ASCENDIS PHARMA A/S	+2.66%	+1.40%	-	-	14.16B
MEDPACE HOLDINGS, INC.	+2.43%	+1.10%	+51.20%	+108.90%	13.01B
EUROFINS SCIENTIFIC SE	+2.77%	+4.02%	+9.61%	+15.31%	12.7B
IONIS PHARMACEUTICALS, INC.	+1.32%	+5.36%	+104.43%	+94.27%	12.54B
Average	+1.99%	-1.40%	+50.39%	+85.58%	21.32B
Weighted average by Cap.	+1.33%	-0.72%	+68.87%	+120.05%

	2024	2025
Net sales	59.69B 38.93M 34.2M 31.52M 29.5M 55.28M 3.69B 56.21M 378M 146M 1.81B 146M 143M 6.29B	64.98B 42.39M 37.24M 34.31M 32.12M 60.18M 4.02B 61.19M 412M 159M 1.97B 159M 156M 6.85B
Net income	3.84B 2.5M 2.2M 2.03M 1.9M 3.55M 237M 3.61M 24.34M 9.42M 116M 9.4M 9.2M 404M	2.59B 1.69M 1.48M 1.37M 1.28M 2.39M 160M 2.43M 16.39M 6.35M 78.38M 6.33M 6.19M 272M
Net Debt	-7.67B -5.01M -4.4M -4.05M -3.79M -7.11M -474M -7.23M -48.65M -18.83M -233M -18.79M -18.39M -809M	-2.67B -1.74M -1.53M -1.41M -1.32M -2.48M -165M -2.52M -16.95M -6.56M -81.07M -6.55M -6.41M -282M